Phillippe Lyrer

Phillippe Lyrer

Auto-generated profile, based on publicly available information

Phillippe Lyrer

15Department of Neurology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2008 in Trials
Verified
Journal Article
Open access
PDF file
PSPeter Sandercock
Peter Sandercock
RLRichard Lindley
Richard Lindley
JWJoanna M Wardlaw
Joanna M Wardlaw
MDMartin Dennis
Martin Dennis
SLSteff Lewis
Steff Lewis
PLPhillippe Lyrer
Phillippe Lyrer
Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24–48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0–2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). ISRCTN25765518

30 November 2011 in Trials
Verified
Journal Article
Open access
PDF file
PSPeter Sandercock
Peter Sandercock
RLRichard Lindley
Richard Lindley
JWJoanna M Wardlaw
Joanna M Wardlaw
MDMartin Dennis
Martin Dennis
KIKaren Innes
Karen Innes
ELErik Lundstrom
Erik Lundstrom
Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in patients with acute ischaemic stroke who meet strictly defined criteria. IST-3 sought to improve the external validity and precision of the estimates of the overall treatment effects (efficacy and safety) of rtPA in acute ischaemic stroke, and to determine whether a wider range of patients might benefit. International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rtPA in acute ischaemic stroke. Suitable patients had to be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracranial haemorrhage and stroke mimics. The initial pilot phase was double blind and then, on 01/08/2003, changed to an open design. Recruitment began on 05/05/2000 and closed on 31/07/2011, by which time 3035 patients had been included, only 61 (2%) of whom met the criteria for the 2003 European approval for thrombolysis. 1617 patients were aged over 80 years at trial entry. The analysis plan will be finalised, without reference to the unblinded data, and published before the trial data are unblinded in early 2012. The main trial results will be presented at the European Stroke Conference in Lisbon in May 2012 with the aim to publish simultaneously in a peer-reviewed journal. The trial result will be presented in the context of an updated Cochrane systematic review. We also intend to include the trial data in an individual patient data meta-analysis of all the relevant randomised trials. The data from the trial will: improve the external validity and precision of the estimates of the overall treatment effects (efficacy and safety) of iv rtPA in acute ischaemic stroke; provide: new evidence on the balance of risk and benefit of intravenous rtPA among types of patients who do not clearly meet the terms of the current EU approval; and, provide the first large-scale randomised evidence on effects in patients over 80, an age group which had largely been excluded from previous acute stroke trials. ISRCTN25765518

1 January 2002 in Journal of Neuroimaging
Verified
Journal Article
Closed access
PDF file
KSK. Schweikert
K. Schweikert
COC. Operschall
C. Operschall
JLJ. B. Llull
J. B. Llull
PLP. Lyrer
P. Lyrer

25 April 1998
Verified
Journal Article
Closed access
PRP Rickenbacher
P Rickenbacher
PLP Lyrer
P Lyrer
KSK Schweikert
K Schweikert
COC Operschall
C Operschall
ASA Steck
A Steck
RRR Ritz
R Ritz